Stable oral pharmaceutical composition of imatinib
The present invention relates to a stable orally disintegrating pharmaceutical formulation comprising imatinib or a pharmaceutically acceptable salt thereof and a one or more pharmaceutically acceptable excipients. The present invention further relates to a stable dispersible pharmaceutical formulation comprising imatinib or a pharmaceutically acceptable salt thereof, and a one or more pharmaceutically acceptable excipients. Moreover, the present invention also relates to a novel pharmaceutical sachet formulation comprising an effective amount of imatinib or a pharmaceutically acceptable salt thereof, a flavouring agent, a sweetener and a one or more pharmaceutically acceptable excipients.
1. A stable oral pharmaceutical composition comprising imatinib, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients selected from the group consisting of diluents, super-disintegrants, binders, lubricants, glidants, sweeteners, flavoring agents, coating agents, taste-masking agents, solvents, and mixtures thereof,
wherein the composition is in the form of orally disintegrating or dispersible tablet,
wherein the super-disintegrant is selected from the group consisting of crospovidone, povidone, sodium starch glycolate, croscarmellose sodium, a low-substituted hydroxypropylcellulose, cross-linked alginic acid, soy polysaccharides, ion-exchange resins, calcium silicate, and mixtures thereof,
wherein the imatinib, or the pharmaceutically acceptable salt thereof, is present in an amount of from about 1 to about 80 wt %, based on the total weight of the composition, and
wherein the composition disintegrates or disperses in purified water in about 60 seconds or less, measured using USP basket method.
2. The pharmaceutical composition according to claim 1 , wherein the imatinib, or the pharmaceutically acceptable salt thereof, is present in an amount of from about 30 to about 80 wt %, based on the total weight of the composition.
3. The pharmaceutical composition according to claim 1 , comprising a super-disintegrant, wherein the super-disintegrant is present in an amount of from about 1 to about 30 wt %, based on the total weight of the composition.
4. The pharmaceutical composition according to claim 1 , comprising a diluent, wherein the diluent is selected from the group consisting of lactose, microcrystalline cellulose, starch, pre-gelatinized starch, calcium phosphate, calcium sulfate, calcium carbonate, mannitol, sorbitol, xylitol, sucrose, maltose, fructose, dextrose, maltodextrin, dextrates, dextrin, and mixtures thereof.
5. The pharmaceutical composition according to claim 1 , comprising a diluent, wherein the diluent is present in an amount of from about 1 to about 80 wt %, based on the total weight of the composition.
6. The pharmaceutical composition according to claim 1 , comprising a binder, wherein the binder is selected from the group consisting of starches, natural and synthetic gums, cellulose derivatives, gelatin, povidone, copovidone, polyethylene glycol, waxes, sodium alginate, alcohols, water, and mixtures thereof.
7. The pharmaceutical composition according to claim 1 , comprising a binder, wherein the binder is present in an amount of from about 0.01 to about 20 wt %, based on the total weight of the composition.
8. The pharmaceutical composition according to claim 1 , comprising a lubricant, wherein the lubricant is selected from the group consisting of calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, light mineral oil, magnesium stearate, mineral oil, polyethylene glycol, stearic acid, zinc stearate, sodium stearyl fumarate, and mixtures thereof.
9. The pharmaceutical composition according to claim 1 , comprising a lubricant, wherein the lubricant is present in an amount of from about 0.1 to about 10 wt %, based on the total weight of the composition.
10. The pharmaceutical composition according to claim 1 , comprising a glidant, wherein the glidant is selected from the group consisting of starches, talc, lactose, stearates, dibasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, colloidal silicon dioxide, and mixtures thereof.
11. The pharmaceutical composition according to claim 1 , comprising a glidant, wherein the glidant is present in an amount of from about 0.1 to about 20 wt %, based on the total weight of the composition.
12. The pharmaceutical composition according to claim 1 , comprising a sweetener, wherein the sweetener is selected from the group consisting of alitame, acesulfame potassium, aspartame, D-tryptophan, dextrose, erythritol, fructose, galactose, glycerol, glycyrrhizin, glucose, isomalt, xylitol, xylose, lactitol, lactose, levulose, maltitol, maltodextrin, maltol, maltose, corn syrup, neohesperidin dihydrochalcone, neotame, sodium saccharin, cyclamate, sorbitol, sucralose, sucrose, tagatose, taumatin, trehalose, and mixtures thereof.
13. The pharmaceutical composition according to claim 1 , comprising a sweetener, wherein the sweetener is present in an amount of about 25 wt % or less, based on the total weight of the composition.
14. The pharmaceutical composition according to claim 1 , comprising a flavoring agent, wherein the flavoring agent is selected from the group consisting of anethole, acetic acid, ascorbic acid, phosphoric acid, fumaric acid, lactic acid, lemon, linalool, malic acid, menthol, eucalyptol, orange, citric acid, cinnamon, tartaric acid, thymol, vanilla, strawberry, cherry flavor (spray dried natural type), chocolate aroma, peppermint aroma, and mixtures thereof.
15. The pharmaceutical composition according to claim 1 , comprising a flavoring agent, wherein the flavoring agent is present in an amount of about 10 wt % or less, based on the total weight of the composition.
16. The pharmaceutical composition according to claim 1 , comprising from about 1% to about 80% w/w of imatinib, or the pharmaceutically acceptable salt thereof, from about 1% to about 80% w/w of diluents, from about 0% to about 20% w/w of binders, from about 1% to about 30% w/w of super-disintegrants, from about 0.1% to about 10% w/w of lubricants, from about 0% to about 20% w/w of glidants, about 25% w/w or less of sweeteners, and about 10% w/w or less of flavoring agents.
17. The pharmaceutical composition according to claim 1 , comprising from about 40% to about 80% w/w of imatinib, or the pharmaceutically acceptable salt thereof, from about 5% to about 20% w/w of diluents, from about 0.5% to about 5% w/w of binders, from about 1% to about 30% w/w of super-disintegrants, from about 0.1% to about 5% w/w of lubricants, from about 0.1% to about 5% w/w of glidants, from about 0.1% to about 2% w/w of sweeteners, and from about 0.1% to about 1% w/w of flavoring agents.
18. The pharmaceutical composition according to claim 1 , wherein the composition is prepared by a process comprising:
a) blending imatinib, or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable fillers, binders, and super-disintegrants to obtain a uniform blend;
b) compacting the uniform blend from Step a) to obtain granules or flakes;
c) blending the granules from Step b) with one or more pharmaceutically acceptable super-disintegrants;
d) lubricating the blend from Step c) with one or more pharmaceutically acceptable lubricants to obtain a lubricated blend; and
e) compressing the lubricated blend from Step d) into tablets.
19. The pharmaceutical composition according to claim 1 , wherein the composition disintegrates or disperses in purified water in about 40 seconds or less, measured using USP basket method.
20. The pharmaceutical composition according to claim 19 , wherein the composition disintegrates or disperses in purified water in about 30 seconds or less, measured using USP basket method.